Digital Look

Welcome to Digital Look++,
you are not logged in

Advanced Search | Company A-Z | Feedback

Shield Therapeutics (STX)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

2.85p

Change Today:

-0.25p
52 Week High: 5.34
52 Week Low: 1.60

Currency: UK Pounds
Shares Issued: 1,041.69m
Volume: 1,771,664

Market Cap: £29.69m
Beta: 0.02

Trade now with Barclays Stockbrokers

Update - Shield Therapeutics is down today can you capitalise from spread betting? Find out more
Update - Shield Therapeutics is a top faller in its sector - can you take advantage with spread betting? Find out more

STX Overview

Shield is a de-risked commercial stage, pharmaceutical company focused on addressing iron deficiency in adults with or without anaemia. Our clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make a difference in their everyday lives.

1 Day Chart (01-07-2025)

6 Month Chart

More Shield Therapeutics charts

Digital Look Charts Sponsored by Barclays Stockbrokers

Financials

	Latest	F'cast
Div Yield	0.0%	0.0%
Div Cover	n/a	n/a
Op Mrgn	-71.1%	-19.7%
ROCE	n/a

	Latest	F'cast
P/E	n/a	n/a
PEG	n/a	n/a
Pr/Revenue	0.9	0.6
Pr/Book	n/a

	Latest	F'cast
Revenue	145.9%	24.1%
PBT	n/a	n/a
EPS	n/a	n/a
DPS	n/a	n/a

STX Fundamentals

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-20	10.39	(1.89)	(1.89)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-21	1.52	(19.91)	(10.00)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-22	5.50	(49.43)	(21.00)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-23	13.09	(32.38)	(5.00)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-24	32.18	(26.56)	(3.00)p	n/a	n/a	n/a	n/a	0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

STX Forecasts

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-25	39.95	(7.89)	(47.42)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-26	59.76	0.66	9.35p	0.3	n/a	n/a	n/a	0.0%
31-Dec-27	90.93	17.42	1.54p	1.8	n/a	-84%	n/a	0.0%

Shield Therapeutics forecasts

STX Company Announcements

Result of AGM	22-May-2025	17:06	RNS
Audited results for the year ended 31 Dec 2024	24-Apr-2025	07:06	RNS
Licence Agreement in Japan for ACCRUFeR®	22-Apr-2025	07:01	RNS

More Shield Therapeutics stx company announcements

STX ShareCast News

Shield Therapeutics inks exclusive licence agree...	22-Apr-2025	ShareCast
Shield Therapeutics appoints Anders Lundstrom as...	27-Jan-2025	ShareCast
Shield Therapeutics secures $10m investment, ann...	06-Dec-2024	ShareCast

More Shield Therapeutics ShareCast news

Latest STX Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 3: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 4: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 5: Forecast figures based on normalised accounts.

STX Market Data

Currency	UK Pounds
Share Price	2.85p
Change Today	-0.25p
% Change	-8.06 %
52 Week High	5.34
52 Week Low	1.60
Volume	1,771,664
Shares Issued	1,041.69m
Market Cap	£29.69m
Beta	0.02